---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-057139"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T22:46:25.355992+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InMed's INM-901 reduces neuroinflammation markers in Alzheimer's ex vivo study

## Summary
- INM-901 statistically significantly reduced pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro in LPS-induced ex vivo model.
- INM-901 significantly reduced inflammasome marker NLRP3, a key contributor to neurodegeneration.
- Reduction of pro-inflammatory markers independent of amyloid beta or tau pathology.
- Company plans to advance INM-901 through additional preclinical studies with IND-enabling studies to follow.

## SEC filing metadata
- accession: 0001213900-25-057139
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025057139/0001213900-25-057139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025057139/ea0246768-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-057139
- JSON: https://secwatch.observer/filing/0001213900-25-057139.json
- Plain text: https://secwatch.observer/filing/0001213900-25-057139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.